Last reviewed · How we verify
CAPMATINIB HYDROCHLORIDE
CAPMATINIB HYDROCHLORIDE is a drug. It is currently FDA-approved (first approved 2020).
At a glance
| Generic name | CAPMATINIB HYDROCHLORIDE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
Key clinical trials
- iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
- INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer (PHASE1)
- A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAPMATINIB HYDROCHLORIDE CI brief — competitive landscape report
- CAPMATINIB HYDROCHLORIDE updates RSS · CI watch RSS
Frequently asked questions about CAPMATINIB HYDROCHLORIDE
What is CAPMATINIB HYDROCHLORIDE?
CAPMATINIB HYDROCHLORIDE is a Small molecule drug.
When was CAPMATINIB HYDROCHLORIDE approved?
CAPMATINIB HYDROCHLORIDE was first approved on 2020.
What development phase is CAPMATINIB HYDROCHLORIDE in?
CAPMATINIB HYDROCHLORIDE is FDA-approved (marketed).
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing